cilostazol has been researched along with Granulocytic Leukemia, Chronic in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite advances in cancer treatment, chronic myeloid leukemia (CML) is still one of the leading causes of death in the world." | 1.72 | Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. ( Naderbar, L; Pazhang, Y; Rezaie, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naderbar, L | 1 |
| Pazhang, Y | 1 |
| Rezaie, J | 1 |
1 other study available for cilostazol and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro.
Topics: AMP-Activated Protein Kinases; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Cilostazol | 2022 |